Exicure Inc (XCUR)

$3.71 +0.06 (1.62%)
Market Cap 22.95M
Revenue (ttm) 500,000.00
Net Income (ttm) -9.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,940.00%
Debt to Equity Ratio 0.00
Volume 4,688
Avg Vol 30,866
Day's Range N/A - N/A
Shares Out 6.37M
Stochastic %K 5%
Beta 3.74
Analysts Strong Buy
Price Target $2.00

Company Profile

Exicure, Inc. does not have significant operations. Previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 847 673 1700
Address:
400 Seaport Court, Suite 102, Redwood City, United States
Bradnum1
Bradnum1 Nov. 14 at 1:49 PM
$XCUR I like this at these prices
0 · Reply
aletz
aletz Nov. 13 at 3:36 PM
$XCUR https://www.biostockinfo.com/biotech-catalyst-ai-scanner-november-wk3/ Exactly same rank as last week. Cash runway seems bit concerning.
0 · Reply
aletz
aletz Nov. 6 at 9:35 PM
$XCUR https://www.biostockinfo.com/biotech-catalyst-ai-scanner-november-wk2/ #12 on the list
0 · Reply
Bolo44
Bolo44 Nov. 6 at 8:34 PM
$XCUR book value is $1.60 only
0 · Reply
LucasHaynes
LucasHaynes Nov. 5 at 5:09 AM
Looking for the next parabolic runner?? Make sure to keep eyes on ticker VEEE .💎 VEEE catching serious attention after that $4.X.25M property sale. Tiny float✅ Clean balance sheet✅ Not many tickers trading under $3.X with real assets and no debt VEE is one💎 The setup here is one of a kind, this has the look to go massive. Make sure not to miss out tomorrow bulls! $ABP $AZTR $XCUR $SLDB ..5
0 · Reply
KingsFourVerseTwentyNine
KingsFourVerseTwentyNine Nov. 4 at 3:39 PM
$XCUR ITS ABOUT TO GET GOOD! https://scitechdaily.com/new-drug-kills-cancer-20000x-more-effectively-with-no-detectable-side-effects/
0 · Reply
Flowjob
Flowjob Oct. 28 at 1:59 PM
$XCUR phase 2 data due any day and Sickle cell partnership news should be before EOY. Interim results 100% (10/10) achieving primary endpoint of successful CD34+ stem cell mobilization.
1 · Reply
MTRADe_01
MTRADe_01 Oct. 7 at 1:09 PM
$GLTO • $CISS • $PALI • $XCUR 🔥 Huge gap moves ahead of open. 🟢 Buy if: price reclaims VWAP + breaks pre-market HOD with RVOL ≥ 2 🔴 Stop if: fails back below ORB / pre-market low with expanding sell volume Follow for live alerts when the real ones fire
0 · Reply
MarketAttack
MarketAttack Sep. 26 at 2:36 PM
$XCUR time to fly
0 · Reply
HustlerTV
HustlerTV Sep. 24 at 9:53 PM
AMS the next penny stock gapper tomorrow, low float with no dilution and undervalued! $XPON $AKTX $AQMS $ZONE $XCUR watching these
1 · Reply
Latest News on XCUR
Exicure, Inc. Reports Third Quarter 2025 Financial Results

Nov 7, 2025, 4:00 PM EST - 7 days ago

Exicure, Inc. Reports Third Quarter 2025 Financial Results

New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting

Nov 3, 2025, 9:00 AM EST - 11 days ago

New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting

Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 22, 2025, 4:15 PM EDT - 23 days ago

Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Exicure Highlights Recent Achievements and Near-term Strategic Priorities

Oct 6, 2025, 7:00 AM EDT - 5 weeks ago

Exicure Highlights Recent Achievements and Near-term Strategic Priorities

Exicure, Inc. Reports Second Quarter 2025 Financial Results

Aug 8, 2025, 4:01 PM EDT - 3 months ago

Exicure, Inc. Reports Second Quarter 2025 Financial Results

Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements

Aug 4, 2025, 4:37 PM EDT - 3 months ago

Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Aug 1, 2025, 4:01 PM EDT - 3 months ago

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Exicure, Inc. Reports First Quarter 2025 Financial Results

Jun 27, 2025, 4:01 PM EDT - 5 months ago

Exicure, Inc. Reports First Quarter 2025 Financial Results

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

May 28, 2025, 4:58 PM EDT - 6 months ago

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

May 5, 2025, 8:00 AM EDT - 6 months ago

Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

Apr 14, 2025, 6:11 PM EDT - 7 months ago

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

Apr 11, 2025, 7:42 PM EDT - 7 months ago

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

Exicure, Inc. Reports Full Year 2024 Financial Results

Mar 18, 2025, 4:01 PM EDT - 8 months ago

Exicure, Inc. Reports Full Year 2024 Financial Results

Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia

Mar 13, 2025, 4:08 PM EDT - 8 months ago

Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia

CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Jan 23, 2025, 12:17 AM EST - 10 months ago

CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Jan 22, 2025, 4:01 PM EST - 10 months ago

Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

Dec 26, 2024, 8:08 PM EST - 11 months ago

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Dec 21, 2024, 1:48 PM EST - 11 months ago

CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Dec 20, 2024, 4:42 PM EST - 11 months ago

Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results

Nov 14, 2024, 4:01 PM EST - 1 year ago

Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results

Exicure, Inc. Receives Extension from Nasdaq Hearings Panel

Sep 18, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Receives Extension from Nasdaq Hearings Panel

Exicure, Inc. Announces 1-for-5 Reverse Stock Split

Aug 26, 2024, 9:08 AM EDT - 1 year ago

Exicure, Inc. Announces 1-for-5 Reverse Stock Split

Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting

Aug 19, 2024, 10:31 AM EDT - 1 year ago

Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting

Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

Aug 15, 2024, 10:31 AM EDT - 1 year ago

Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

Exicure, Inc. Reports Second Quarter 2024 Financial Results

Aug 13, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Reports Second Quarter 2024 Financial Results

Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics

Aug 8, 2024, 4:27 PM EDT - 1 year ago

Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics

Exicure, Inc. Receives Positive Listing Determination from Nasdaq

Aug 1, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Receives Positive Listing Determination from Nasdaq

Exicure, Inc. Reports First Quarter 2024 Financial Results

Jun 17, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Reports First Quarter 2024 Financial Results

Exicure, Inc. Reports Full Year 2023 Financial Results

Jun 6, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Reports Full Year 2023 Financial Results

Exicure, Inc. Received Nasdaq Notice of a Delisting Determination

May 23, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Received Nasdaq Notice of a Delisting Determination

Exicure, Inc. Reports Third Quarter 2023 Financial Results

May 16, 2024, 4:08 PM EDT - 1 year ago

Exicure, Inc. Reports Third Quarter 2023 Financial Results

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K

Apr 22, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis

Feb 5, 2024, 4:01 PM EST - 1 year ago

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis

Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors

Aug 23, 2023, 9:48 AM EDT - 2 years ago

Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors

Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 11, 2023, 4:01 PM EDT - 2 years ago

Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

Jul 14, 2023, 4:01 PM EDT - 2 years ago

Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives

May 26, 2023, 4:01 PM EDT - 2 years ago

Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives

Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld

May 4, 2023, 4:01 PM EDT - 2 years ago

Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld

Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update

Mar 27, 2023, 4:01 PM EDT - 2 years ago

Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update

Exicure, Inc. Announces Closing of Private Placement Transaction with CBI USA, Inc. and Changes to the Board of Directors

Feb 24, 2023, 5:10 PM EST - 2 years ago

Exicure, Inc. Announces Closing of Private Placement Transaction with CBI USA, Inc. and Changes to the Board of Directors

Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements

Dec 14, 2022, 5:00 AM EST - 3 years ago

Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements

Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 14, 2022, 4:01 PM EST - 3 years ago

Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives

Sep 26, 2022, 4:01 PM EDT - 3 years ago

Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives

Exicure Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference

Sep 1, 2022, 7:00 AM EDT - 3 years ago

Exicure Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference

Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress

Aug 15, 2022, 4:01 PM EDT - 3 years ago

Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress

Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 20, 2022, 4:01 PM EDT - 3 years ago

Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

Exicure, Inc. Announces Receipt of Nasdaq Notice of Non-compliance and Implementation of One-for-Thirty Reverse Stock Split

Jun 29, 2022, 12:00 PM EDT - 3 years ago

Exicure, Inc. Announces Receipt of Nasdaq Notice of Non-compliance and Implementation of One-for-Thirty Reverse Stock Split

Exicure, Inc. Announces Adjournment of Annual Meeting of Stockholders

May 27, 2022, 4:01 PM EDT - 3 years ago

Exicure, Inc. Announces Adjournment of Annual Meeting of Stockholders

Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference

May 17, 2022, 7:00 AM EDT - 3 years ago

Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference

Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate Progress

May 16, 2022, 4:01 PM EDT - 3 years ago

Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate Progress

Bradnum1
Bradnum1 Nov. 14 at 1:49 PM
$XCUR I like this at these prices
0 · Reply
aletz
aletz Nov. 13 at 3:36 PM
$XCUR https://www.biostockinfo.com/biotech-catalyst-ai-scanner-november-wk3/ Exactly same rank as last week. Cash runway seems bit concerning.
0 · Reply
aletz
aletz Nov. 6 at 9:35 PM
$XCUR https://www.biostockinfo.com/biotech-catalyst-ai-scanner-november-wk2/ #12 on the list
0 · Reply
Bolo44
Bolo44 Nov. 6 at 8:34 PM
$XCUR book value is $1.60 only
0 · Reply
LucasHaynes
LucasHaynes Nov. 5 at 5:09 AM
Looking for the next parabolic runner?? Make sure to keep eyes on ticker VEEE .💎 VEEE catching serious attention after that $4.X.25M property sale. Tiny float✅ Clean balance sheet✅ Not many tickers trading under $3.X with real assets and no debt VEE is one💎 The setup here is one of a kind, this has the look to go massive. Make sure not to miss out tomorrow bulls! $ABP $AZTR $XCUR $SLDB ..5
0 · Reply
KingsFourVerseTwentyNine
KingsFourVerseTwentyNine Nov. 4 at 3:39 PM
$XCUR ITS ABOUT TO GET GOOD! https://scitechdaily.com/new-drug-kills-cancer-20000x-more-effectively-with-no-detectable-side-effects/
0 · Reply
Flowjob
Flowjob Oct. 28 at 1:59 PM
$XCUR phase 2 data due any day and Sickle cell partnership news should be before EOY. Interim results 100% (10/10) achieving primary endpoint of successful CD34+ stem cell mobilization.
1 · Reply
MTRADe_01
MTRADe_01 Oct. 7 at 1:09 PM
$GLTO • $CISS • $PALI • $XCUR 🔥 Huge gap moves ahead of open. 🟢 Buy if: price reclaims VWAP + breaks pre-market HOD with RVOL ≥ 2 🔴 Stop if: fails back below ORB / pre-market low with expanding sell volume Follow for live alerts when the real ones fire
0 · Reply
MarketAttack
MarketAttack Sep. 26 at 2:36 PM
$XCUR time to fly
0 · Reply
HustlerTV
HustlerTV Sep. 24 at 9:53 PM
AMS the next penny stock gapper tomorrow, low float with no dilution and undervalued! $XPON $AKTX $AQMS $ZONE $XCUR watching these
1 · Reply
MarketAttack
MarketAttack Sep. 19 at 1:58 PM
$XCUR Back to 12$ Incredible news are coming
1 · Reply
MarketAttack
MarketAttack Sep. 18 at 2:14 PM
$XCUR go to 10$
0 · Reply
KunalSingh
KunalSingh Sep. 16 at 4:06 PM
I don’t have much hope for small caps boomed stock unless they crack a Phase 1, 2, or 3 trial. Last year I traded $XCUR, which did a similar debt-to-stock deal to clean up their books. I waited patiently as the stock moved from $2.1 → $1.4 → $6 → $4 → $10, and eventually hit $33. I played it a few times, but the key win was validating my trading thesis which matters more than random scalping gains.
0 · Reply
MarketAttack
MarketAttack Sep. 16 at 2:00 PM
$XCUR to 10$ this week
1 · Reply
MarketAttack
MarketAttack Sep. 15 at 11:41 PM
$XCUR Journey back to 10$...has just started
0 · Reply
MarketAttack
MarketAttack Sep. 15 at 5:48 PM
$XCUR go monster...your time is coming
0 · Reply
MarketAttack
MarketAttack Sep. 15 at 5:00 PM
$XCUR go beast go
0 · Reply
MarketAttack
MarketAttack Sep. 15 at 4:41 PM
$XCUR Very bullish on that from here...long and holding
0 · Reply
MarketAttack
MarketAttack Sep. 15 at 4:40 PM
$XCUR A journey to 10$ back is starting
0 · Reply
GluttonBoy
GluttonBoy Sep. 9 at 5:53 PM
TAIT stock is at zero borrow with shorts trapped and about to have a historic squeeze 3M float with no dilution and is a profitable semiconductor play $XCUR $AIRG $NRSN $PC $EONR on watch rn
0 · Reply
GluttonBoy
GluttonBoy Sep. 9 at 5:27 PM
TAIT stock is at zero borrow with shorts trapped and about to have a historic squeeze 3M float with no dilution and is a profitable semiconductor play Also looking at : $LITB $XCUR $SSKN $SJ $NYC
0 · Reply